Research To Practice | Oncology Videos

Latest Episodes:

HER2-Positive and Triple-Negative Breast Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer Mar 15, 2024

Show notes

Featuring perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics:

Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00)
HER2-Positive Breast Cancer — Dr Krop (12:30)
Triple-Negative Breast Cancer — Dr Sharma (36:34)

CME information and select publications

Metastatic Urothelial Bladder Cancer | Virtual Case Library: Metastatic Urothelial Bladder Cancer Mar 13, 2024

Show notes

Featuring perspectives from Dr Petros Grivas, Dr Vadim S Koshkin, Dr Kriti Mittal, Dr Mamta Parikh and Dr Scott T Tagawa, including the following topics:

First-Line Treatment of Metastatic Urothelial Bladder Cancer (mUBC) — Enfortumab Vedotin/Pembrolizumab

Case: A man in his late 80s with recurrent unresectable locally advanced UBC receives first-line enfortumab vedotin and pembrolizumab — Dr Parikh (0:00)
Case: A woman in her mid 60s with newly diagnosed mUBC attains an excellent response with first-line enfortumab vedotin and pembrolizumab — Dr Mittal (12:14)

Other Approaches to First-Line Treatment of mUBC — Nivolumab/Chemotherapy

Case: A man in his mid 70s with multiregimen-recurrent mUBC attains a complete response to enfortumab vedotin monotherapy — Dr Koshkin (25:22)
Case: A man in his mid 70s with muscle-invasive bladder cancer with 50% squamous histology receives adjuvant nivolumab — Dr Mittal (35:07)
Comparing new first-line treatments for previously untreated unresectable or metastatic UBC: Brentuximab vedotin/pembrolizumab and nivolumab/chemotherapy (43:18)

Integrating Enfortumab Vedotin Monotherapy into the Treatment of mUBC

Case: A man in his late 70s with recurrent mUBC and disease progression after treatment on 2 clinical trials experiences a complete response with enfortumab vedotin monotherapy — Dr Parikh (48:15)
Monitoring and management of enfortumab vedotin-associated dermatologic and neurologic side effects (50:53)
Case: A woman in her early 60s with multiregimen-refractory mUBC — Dr Mittal (59:26)

Integrating Sacituzumab Govitecan into the Treatment of mUBC

Case: A woman in her late 70s with multiregimen-refractory mUBC experiences an ongoing response with dose-reduced sacituzumab govitecan — Dr Koshkin (1:05:26)
Case: A man in his late 60s with relapsed/refractory mUBC receives fifth-line sacituzumab govitecan — Dr Parikh (1:15:09)

FGFR-Targeted Therapy for mUBC — Erdafitinib

Case: A man in his mid 70s with relapsed/refractory mUBC with an FGFR3 mutation receives erdafitinib — Dr Koshkin (1:29:36)

HER2-Targeted Therapy for mUBC — Trastuzumab Deruxtecan, Disitamab Vedotin

Case: A man in his early 60s with relapsed/refractory mUBC with HER2 amplification experiences intolerable toxicities with enfortumab vedotin — Dr Parikh (1:43:25)
Case: A woman in her mid 70s with relapsed/refractory HER2-low mUBC — Dr Koshkin (1:56:36)

CME information and select publications

ER-Positive Metastatic Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer (Companion Faculty Lecture) Mar 11, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Komal Jhaveri, including the following topics:

Role of ESR1 mutations in sensitivity and resistance to endocrine therapy in patients with ER-positive metastatic breast cancer (0:00)
Efficacy and safety of oral SERDs in patients with ER-positive metastatic breast cancer (13:26)
Similarities and differences among available and investigational oral SERDs for ER-positive metastatic breast cancer (24:21)

CME information and select publications

Show notes

Featuring an interview with Dr Komal Jhaveri, including the following topics:

Case: A woman in her mid 50s with ER-positive, HER2-low (IHC 1+) metastatic breast cancer with an ESR1 mutation (0:00)
Case: A woman in her late 40s with ER-positive, HER2-low ESR1 wild-type metastatic breast cancer who received imlunestrant on a clinical trial (7:25)
Case: A woman in her early 60s with a history of localized breast cancer who received imlunestrant and abemaciclib on a trial for newly diagnosed metastatic breast cancer after disease progression on endocrine therapy (12:03)
Beyond the Guidelines: A survey of clinical investigator perspectives on the current and future role of oral SERDs (selective estrogen receptor degraders) for ER-positive metastatic breast cancer (17:35)

CME information and select publications

Myelofibrosis | Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series Mar 08, 2024

Show notes

Featuring perspectives from Dr Stephen T Oh, including the following topics:

Introduction: ASH 2023 Update (0:00)
Case: A woman in her early 70s with symptomatic primary myelofibrosis (MF) receives ruxolitinib — Rao Mushtaq, MD (15:41)
Case: A woman in her late 60s, a Jehovah's Witness with multiple comorbidities, presents with splenomegaly and anemia and is diagnosed with primary MF — Bhavana (Tina) Bhatnagar, DO (27:16)
Case: A woman in her mid 70s who received pacritinib for 4 years on trial now experiences disease progression with massive splenomegaly and thrombocytopenia (20K-30K) — Neil Morganstein, MD (31:50)
Case: A woman in her late 50s with symptomatic primary MF has normal cytogenetics and JAK2 and DNMT3A mutations — Jeanne Palmer, MD (35:45)
Case (continued): A woman in her late 50s has progressive MF after ruxolitinib and fedratinib; repeat next-generation sequencing shows JAK2, DNMT3A, IDH2 and TET2 mutations — Dr Palmer (41:09)
Case: A woman in her late 60s with primary MF who discontinued ruxolitinib due to onset of congestive heart failure now has possible acute myeloid leukemia transformation — Dr Bhatnagar (50:38)
Case: A woman in her late 60s with well controlled MF who has received 10 mg of ruxolitinib twice a day for 3 years develops increasing anemia and splenomegaly — Dr Palmer (52:38)

CME information and select publications

Gastroesophageal Cancers | Yelena Y Janjigian, MD Mar 07, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 1: Immunotherapy in Gastroesophageal Cancers — Yelena Y Janjigian, MD

CME information and select publications

Gastroesophageal Cancers | Zev Wainberg, MD, MSc Mar 07, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers | Faculty Presentation 2: Other Treatment Approaches for Gastroesophageal Cancers — Zev Wainberg, MD, MSc

CME information and select publications

Gastroesophageal Cancers | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers Mar 07, 2024

Show notes

Featuring perspectives from Dr Yelena Y Janjigian and Dr Zev Wainberg, including the following topics:

Introduction: First-Line Therapy for Metastatic Gastroesophageal (GE) Cancers — the Bottom Line (0:00)
Updates on Immunotherapy in GE Cancers (18:51)
Targeting HER2 (33:11)
Targeting Claudin 18.2 — Zolbetuximab (54:42)

CME information and select publications

Chronic Lymphocytic Leukemia | Jeff Sharman, MD Feb 27, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 1: Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD

CME information and select publications

Chronic Lymphocytic Leukemia | Lindsey Roeker, MD Feb 27, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Chronic Lymphocytic Leukemia | Faculty Presentation 2: Future Directions in the Care of Patients with CLL — Lindsey Roeker, MD

CME information and select publications